NCT02690181View on ClinicalTrials.gov

Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 29, 2016

Primary Completion Date

November 2, 2016

Study Completion Date

November 2, 2016

Conditions
Bacterial Infection Due to Streptococcus, Group BStreptococcus Agalactiae
Interventions
BIOLOGICAL

GBS Trivalent Vaccine

Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02690181 - Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects. | Biotech Hunter | Biotech Hunter